| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 515.2MM | +3% |
| Gross Profit | 506.7MM | - |
| Cost Of Revenue | 8.5MM | -24% |
| Operating Income | 150.3MM | +6% |
| Operating Expenses | 356.4MM | - |
| Net Income | 147.7MM | +78% |
| R&D | 137.5MM | -3% |
| G&A | 218.9MM | +7% |
| Interest Expense | 1.1MM | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Top-notch biotech stock Neurocrine surged Tuesday after analysts suggested the company's depression treatment could rival ketamine.
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the community in managing the condition.
Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 1, 2024.
In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]
Neurocrine Biosciences' (NASDAQ:NBIX) stock is up by 4.9% over the past month. Given its impressive performance, we...